Positive News Coverage Extremely Likely to Impact Conatus Pharmaceuticals (CNAT) Share Price

Headlines about Conatus Pharmaceuticals (NASDAQ:CNAT) have been trending positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Conatus Pharmaceuticals earned a news impact score of 0.31 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 100 out of 100, meaning that recent press coverage is extremely likely to have an impact on the stock’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s analysis:

Insider Buying and Selling by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Several research analysts have recently issued reports on the stock. Aegis restated a “buy” rating and set a $11.00 price objective on shares of Conatus Pharmaceuticals in a report on Friday, May 5th. ValuEngine upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 24th. Stifel Nicolaus restated a “buy” rating and set a $9.00 price objective (up previously from $7.00) on shares of Conatus Pharmaceuticals in a report on Thursday, March 16th. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 14th. Finally, FBR & Co restated an “outperform” rating and set a $16.00 price objective on shares of Conatus Pharmaceuticals in a report on Wednesday, March 15th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Conatus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $13.25.

Shares of Conatus Pharmaceuticals (NASDAQ CNAT) opened at 5.10 on Monday. Conatus Pharmaceuticals has a 12 month low of $1.45 and a 12 month high of $9.40. The stock’s 50 day moving average is $5.66 and its 200 day moving average is $5.14. The firm’s market capitalization is $133.46 million.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.20. The business had revenue of $7 million for the quarter, compared to the consensus estimate of $5.88 million. During the same period in the prior year, the business posted ($0.35) earnings per share. Equities research analysts forecast that Conatus Pharmaceuticals will post ($0.70) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by BBNS and is owned by of BBNS. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/positive-news-coverage-extremely-likely-to-impact-conatus-pharmaceuticals-cnat-share-price/1094740.html.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Hitters in Major League Baseball on Record Home Run Pace
Hitters in Major League Baseball on Record Home Run Pace
Atlanta Considering Playing Freddie Freeman at Third
Atlanta Considering Playing Freddie Freeman at Third
Injury to Gleyber Torres Adds to Questions About Yankees
Injury to Gleyber Torres Adds to Questions About Yankees
Game Winning Home Run Completes Nolan Arenado Cycle
Game Winning Home Run Completes Nolan Arenado Cycle
New York Yankees and Masahiro Tanaka Hit Hard Again
New York Yankees and Masahiro Tanaka Hit Hard Again
Victor Martinez Diagnosed with Irregular Heartbeat
Victor Martinez Diagnosed with Irregular Heartbeat


Leave a Reply

 
© 2006-2017 BBNS.